Phathom Pharmaceuticals, Inc. Dividends (Preferred)

Dividends (Preferred) of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Dividends (Preferred) growth rates and interactive chart. Preferred dividends are the dividends that are accrued paid on a company's preferred stock. Any time a company pays dividends, preferred shareholders have priority over common shareholders, which means dividends must always be paid to preferred shareholders before they are paid to common shareholders

Highlights and Quick Summary

  • Annual Dividends (Preferred) for 2019 was $0
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Dividends (Preferred) of Phathom Pharmaceuticals, Inc.

Most recent Dividends (Preferred)of PHAT including historical data for past 10 years.

Interactive Chart of Dividends (Preferred) of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Dividends (Preferred) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 – – – – $0.0

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
© stockrow.com